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Telomerase, the enzyme that elongates our telomeres, is crucial for cancer 
development based on extensive analyses of human cells, human cancers, and 
mouse models. New data now suggest that a viral telomerase RNA gene en-
coded by Marek’s disease virus (MDV), an oncogenic herpesvirus of chickens, 
promotes tumor formation. These fi  ndings highlight the importance of telom-
erase in cancer and raise new questions regarding the mechanisms by which 
the telomerase RNA component supports tumorigenesis. 
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Marek’s disease virus and lymphoma
Many of our fi  rst insights into oncogenes 
and tumor suppressor genes—genes 
dys  regulated in human cancer—came 
from studies of cancer-causing vi-
ruses. The discovery that the potent 
tumorigenicity of transforming avian 
retroviruses is caused by capture of 
cellular oncogenes led to the identi-
fi  cation of the proto  oncogenes c-myc 
and src, among   others. An alternative 
tumorigenic strategy is used by DNA 
tumor viruses, such as SV40 virus and 
human papilloma virus, which encode 
their own oncoproteins that inacti-
vate key tumor suppressor proteins, in  -
cluding p53 and Rb (1). In humans, 
herpes family viruses represent an im-
portant class of viruses that can induce 
cancer, principally in patients whose 
immune systems are suppressed by 
medications or HIV. Examples include 
Epstein-Barr virus, which can induce 
lymphoma, and human herpesvirus 
(HHV)8, the causative agent of Kapo-
si’s sarcoma. These large DNA viruses 
can also stably acquire viral versions 
of host genes and use them to help 
transform human cells. For example, 
HHV8 expresses a viral D-type cyclin 
and a viral version of the growth fac-
tor NF-IL6 (2). Given the already im-
pressive progress in understanding the 
mechanisms of viral transformation, is 
it likely that there are important clues 
to understanding cancer development 
that remain to be discovered through 
analysis of transforming viruses? The 
answer is undoubtedly yes, as revealed 
by recent work on MDV, an onco-
genic herpesvirus that infects chickens. 
Infection with MDV leads to neuro-
logic disease and rapid development of 
lymphoma (3). The virus was recently 
found to contain two identical copies 
of a viral telomerase RNA component 
(vTR), which were appropriated from 
the chicken genome, suggesting the 
tantalizing possibility that vTR acts as 
an oncogene (4).
Telomerase, telomere shortening, 
and cancer
Telomerase comprises two essential 
subunits: the telomerase reverse tran-
scriptase (TERT), and the telomerase 
RNA component (TR) (5). TR en-
codes the template sequence that is 
reverse transcribed by telomerase onto 
chromosome ends during telomere 
elongation. Together, TERT and TR 
represent the catalytic core of the en-
zyme required for addition of telomere 
sequences—TTAGGG nucleotide re-
peats in mammals and birds. In the ab-
sence of suffi   cient levels of telomerase, 
telomeres shorten with each cell divi-
sion because of the inability of DNA 
polymerase to copy the end of the lag-
ging DNA strand—known as the end 
replication problem. With continued 
telomere shortening in human fi  bro-
blast cultures, telomeres undergo a 
conformational change—telomere un-
capping—that causes replicative senes-
cence, a form of cell cycle arrest and 
altered gene expression requiring the 
p53 and Rb tumor suppressor path-
ways. Loss of p53 and Rb enables cell 
proliferation beyond this senescence 
checkpoint, but continued telomere 
shortening ultimately results in covalent 
ligation of telomere ends, as telomeres 
can no longer suppress recombination. 
This state—termed telomere-based 
  crisis—is characterized by high rates of 
programmed cell death and chromo-
somal instability.
Telomere shortening also occurs in 
human tissues with advancing age, per-
haps caused by restricted expression 
patterns of telomerase. Telomerase is 
active in the germline, but is limited in 
expression in many adult tissues to stem 
cells and progenitor cells (6). Although 
telomerase is repressed in most somatic 
cells, it is reactivated in  90% of hu-
man cancers (7). Much of this regula-
tion appears to center on transcriptional 
control of the TERT component, 
which is restricted in its expression. In 
contrast, TR is expressed more broadly, 
leading to the generally held belief 
that TERT is a limiting component for 
telomerase activity. Telomerase expres-
sion is critical for tumor development. 
For example, expression of TERT is 
suffi     cient to immortalize primary hu-
man cells (8) and is required for ex-
perimental transformation of primary 
human cells expressing numerous on-
cogenes (9). In addition, telomerase 
knockout mice with short telomeres 
exhibit profound resistance to tumori-
genesis (10, 11). Although these and 
other fi  ndings defi  nitively link telom-
erase to immortal proliferation and 
cancer, many of the genetic changes 
associated with classical oncogenes—
mutation, amplifi  cation, or expression 
by transforming viruses—have been 
lacking for telomerase components.1144  TELOMERASE RNA COMPONENT AS A VIRAL-ENCODED ONCOGENE | Artandi
Potential oncogenic mechanisms of vTR
This discrepancy is what makes the 
fi  ndings of Trapp et al. in this issue (p. 
1307) so important to the study of te-
lomerase and cancer (12). The authors 
set out to address whether the vTR 
genes in MDV are important in malig-
nant transformation by the virus. The 
two vTR genes are 88% identical to the 
chicken TR gene (cTR) (4). The vTR 
gene, when expressed in mouse cells 
defi   cient in mouse TR, reconstituted 
telomerase activity, indicating that vTR 
is capable of supporting telomerase 
  enzymatic activity. Trapp et al. deleted 
both copies of vTR in an oncogenic 
strain of MDV and found that lym-
phomagenesis in infected chickens was 
reduced by 60% in the vTR deletion 
strains compared with wild-type virus. 
Furthermore, when animals infected 
with the vTR deletion strains did de-
velop lymphoma, these cancers were 
smaller in size and less widely dissemi-
nated. Importantly, deletion of vTR did 
not impair lytic replication of the virus, 
indicating that vTR serves a role sup-
porting lymphomagenesis, rather than 
viral replication (12). Thus, the vTR 
gene exhibits attributes of an oncogene, 
enhancing the incidence and severity of 
lymphoma caused by MDV.
These important fi  ndings raise a se-
ries of new questions centered on the 
problem of how and why expression 
of vTR in MDV is oncogenic. The 
most straightforward interpretation is 
that vTR enhances telomerase activity 
leading to stabilization of telomeres. 
  According to this model, a subset of 
telomeres in lymphoid cells infected 
with MDV must become critically 
short. In the absence of vTR, telomere 
uncapping in these lymphocytes would 
reduce tumor formation, whereas in 
wild-type MDV strains that express 
vTR, lengthening of these short telo-
meres would allow full malignant po-
tential. Consistent with this idea, vTR 
was shown to yield increased telom-
erase activity compared with cTR, 
when combined in vitro with recom-
binant chicken TERT protein (13). 
This model implies that in the target 
lymphocyte population cTR levels are 
limiting and TERT protein is in excess, 
such that telomerase activity rises when 
vTR is expressed from the virus. Alter-
natively, another viral gene may lead to 
stimulation of endogenous TERT lev-
els enabling increased telomerase when 
coupled with expression of vTR.
Another distinct possibility is that 
vTR acts through a mechanism that 
is independent of telomere synthesis. 
Emerging evidence from several labora-
tories has indicated that telomerase has 
additional roles independent of telomere 
length. Transgenic expression of TERT 
in mice led to an increased number 
of carcinogen-induced skin papillomas 
(14) and to an elevated incidence of 
spontaneous breast cancers (15). Since 
mouse telomeres are suffi   ciently  long 
that telomere uncapping does not occur 
in mouse tissues, these prooncogenic ef-
fects of TERT are not thought to require 
telomere elongation. In human cells 
that maintain their telomeres through 
a telomerase-independent mechanism 
(known as alternative lengthening of 
telomeres [ALT]), expression of TERT 
was necessary for malignant transforma-
tion and growth of tumors in immuno-
compromised mice (16). This eff  ect of 
TERT in ALT cells appears to extend to 
TR as well, as overexpression of mouse 
TR was necessary to enable mouse 
ALT cells from TR−/− mice to grow 
effi   ciently as metastatic nodules in lung 
(17). These results are reminiscent of the 
current fi  ndings in MDV.
In addition to these cancer-causing 
activities, telomerase has recently been 
found to exhibit profound eff  ects  on 
stem cells in mouse skin (18, 19). Con-
ditional expression of TERT in mouse 
skin led to activation of quiescent stem 
cells in the hair follicle and a rapid de-
velopmental change in the follicle from 
the resting phase (telogen) to the active 
phase of the hair follicle cycle (anagen) 
(18). Induction of anagen by TERT 
facilitated robust hair growth. These 
eff  ects of TERT did not require TR 
and were therefore genetically sepa-
rable from TERT’s well-understood 
role in elongating telomeres. Could 
TR also exhibit activities independent 
of its role in serving as a template for 
telomere addition that might explain its 
transforming activity in MDV? Recent 
loss-of-function data in human cancer 
cells lines support this idea. Depletion 
of human TR (hTR) through RNA 
  interference in human cancer cell lines 
reduced the rate of cell proliferation. 
This eff  ect of hTR depletion was not 
caused by telomere uncapping, as there 
was no evidence of telomere dysfunc-
tion, such as an increase in DNA dam-
age foci (20, 21). Instead, cells treated 
with hTR siRNA showed a marked 
change in gene expression profi  les that 
may explain the eff  ect of hTR deple-
tion. Thus, the deleterious, telomere 
length-independent eff  ect of hTR loss 
on cancer cell proliferation could repre-
sent the fl  ip side of the prooncogenic ef-
fects of vTR overexpression in MDV.
Future questions
The fi  ndings of Trapp et al. suggest several
high priority experiments to address the 
mechanism of vTR’s transforming ac-
tivity (12). It will be critical, for example, 
to determine if vTR contributes to lym-
phomagenesis by extending telomeres. 
One genetic approach to this question 
would be to determine if chicken TERT 
is required for vTR’s eff  ects. Alterna-
tively, one could dissect the sequence 
requirements within vTR necessary for 
complementing vTR-  defi  cient  MDV 
in transformation. Through deletion 
or mutation approaches, one can test if 
vTR’s templating function is required 
for lymphomagenesis. An equally in-
teresting question is whether vTR’s 
activities in supporting lymphoma 
development are shared with its cel-
lular counterpart cTR. If cTR cannot 
restore the full transforming activity 
of the vTR-  defi  cient MDV strains, it 
would argue that the few sequence dif-
ferences between the two genes are im-
portant in transformation. Ultimately, 
understanding how vTR supports lym-
phomagenesis in genetic and molecular 
terms will yield important new insights 
into telomerase function in cancer.
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